CME Presentations

Severe Asthma



  • Michael Wechsler, MD, MMSc

    Michael Wechsler, MD, MMSc

    Michael Wechsler, MD, MMSc

    Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine

    Michael Wechsler, MD, MMSc, is a Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health (NJH), Director of the NJH/Cohen Family Asthma Institute, and Associate Vice President for Innovation and Industry Relations at NJH. In addition to clinical work in pulmonary & critical care medicine, Dr. Wechsler’s research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome, CSS). He has led studies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab.
  • Jonathan Corren, MD

    Jonathan Corren, MD

    Jonathan Corren, MD

    Department of Medicine and Pediatrics

  • Sanaz Eftekhari

    Sanaz Eftekhari

    Sanaz Eftekhari

    Vice President of Corporate Affairs and Research

    Sanaz Eftekhar, vice president of Corporate Affairs and Research at AAFA, leads tactical and strategic conversations with business partners and stakeholders across multiple industries. She has been instrumental in working with AAFA’s partners to present patient perspectives on the needs for atopic dermatitis treatments to the US Food and Drug Administration. In a greater effort to connect patients with vital clinical trials, Sanaz has been a key player in the development of AAFA’s upcoming clinical trial database. She has led AAFA’s involvement in the CIU & You campaign since its launch in 2015, co-authored several key AAFA research reports, and serves as secretary on the Board of Directors for the Global Allergy & Airways Patient Platform (GAAPP).

CME Information

Global LogoPQH Logo

Biologic Therapy for Patients with Severe Asthma: Impeding the Inflammatory Cascade

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA)


This activity is supported by an educational grant from AstraZeneca.


This activity was released on August 23, 2022 and is valid until August 23, 2023. Requests for credit must be made no later than August 23 2023


The target audiences for the proposed HCP activity are immunologists, allergists, primary care providers, pediatricians, specialty and non-specialty NPs and PAs, pharmacists, and other members of the multi-disciplinary care team


The development of modern biological therapies has revolutionized severe asthma management, but a subset of asthma patients remains symptomatic with poor quality of life and heavy healthcare use. New insights into the role of TSLP in asthma have led to the development of a novel therapy that targets the underlying drivers of inflammation and may alleviate some of this burden on patients.

Join an expert panel of clinicians and patient representatives to review the roles of the various inflammatory pathways in severe asthma, along with the mechanisms of action of various therapies, their safety and efficacy data, and how a new treatment option targeting TSLP can be integrated into the asthma-management armamentarium. Panelists will share strategies to effectively identify those patients most likely to benefit from current and emerging therapies and then select the most appropriate biologic for each patient with severe asthma.

Do you have patients with asthma who could benefit from related education on current and future therapies to reduce exacerbations and gain control of their symptoms? Direct your patients to to access the patient-education activity, “Breathe Easier with Asthma.”


After completing this activity, the participant should be better able to:
  • Identify how epithelial alarmins impact T2 and non-T2 downstream inflammation in asthma
  • Differentiate the mechanisms of action of available biologics for severe asthma
  • Summarize efficacy and safety data related to alarmin blockade with biologic therapy against TSLP
  • Identify which patients could benefit from treatment that targets TSLP


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Jonathan Corren, MD
Department of Medicine and Pediatrics,
David Geffen School of Medicine at UCLA,
University of California
Consulting Fee (e.g., Advisory Board): AstraZeneca, Regeneron, Sanofi
Contracted Research: Amgen, AstraZeneca, Novartis, OptiNose, Regeneron, Sanofi,Teva
Speakers Bureau: AstraZeneca,Amgen Regeneron, Sanofi
Michael Wechsler, MD
Director of The Cohen Family Asthma Institute
National Jewish Health
Consulting Fee (e.g., Advisory Board): Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason Eli Lilly, Equillium, Glaxosmithkline, Incyte, Kinaset Novartis, Om Pharma, Phylaxis, Pulmatrix Rapt Therapeutics, Regeneron, Restorbio Roche/Genentech, Sanofi/Genzyme, Sentien Sound Biologics, Tetherex Pharmaceuticals Teva. Upstream Bio
Honoraria: AstraZeneca, GSK, Sanofi, Regeneron
Sanaz Eftekhari
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of America
Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Lauren Sinclair Nothing to disclose
Carole Drexel Nothing to disclose
Eve Wilson Nothing to disclose
Caroline Laurendeau Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at